Results 81 to 90 of about 17,566 (194)

On‐Chip Evaluation of Red Blood Cell Deformability Through Transit Velocity Index in Hematological Diseases

Small, Volume 22, Issue 33, 12 June 2026.
The deformability of red blood cell is essential for smooth microcirculation. We propose a deformability index using a microfluidic platform with capillary‐like constrictions, based on the relationship between cell deformation and transit velocity through the constrictions. Its effectiveness and clinical potential have been demonstrated in applications
Kenji Kajitani, Chia‐Hung Dylan Tsai, Tomohito Ohtani, Shigeo Wada, Ivan Cimrák, Misato Chimura, Tatsunori Taniguchi, Yasutaka Ueda, Jun‐ichi Nishimura, Yasushi Sakata   +9 more
wiley   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

British Journal of Haematology, Volume 208, Issue 6, Page 2036-2046, June 2026.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler, Marion Malphettes, Véronique Meignin, David Boutboul, Lionel Galicier   +4 more
wiley   +1 more source

Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study

European Journal of Haematology, Volume 116, Issue 6, Page 850-862, June 2026.
ABSTRACT Background Individuals with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) face transformation risks to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). While older age is linked to increased risk, it remains unclear whether risk increases with age or with disease duration.
Nurgul Batyrbekova, Anna Ravn Landtblom, Malin Hultcrantz, Robert Szulkin, Paul W. Dickman, Therese M.‐L. Andersson   +5 more
wiley   +1 more source

Genomic Landscape Analysis of Canine Pulmonary Adenocarcinoma Reveals Candidate Targetable Gene Fusions

Veterinary and Comparative Oncology, Volume 24, Issue 2, Page 393-406, June 2026.
ABSTRACT Spontaneously occurring primary canine pulmonary adenocarcinoma (cPAC) exhibits clinicopathological and molecular similarities to never‐smoker human lung cancers. Shared genomic alterations, including point mutations, indel mutations and copy number changes particularly in HER2 signalling, are significant therapeutic targets, especially for ...
Sharadha Sakthikumar, William P. D. Hendricks, David Rainford, William Selleck, Natalia Briones, Christopher Coggins, Natalie Quan, Victoria Zismann, Gwendolen Lorch, Aleksandar Sekulic, Jeffrey M. Trent   +10 more
wiley   +1 more source

Primary myelofibrosis: current therapeutic options

Revista Brasileira de Hematologia e Hemoterapia
Primary myelofibrosis is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid expansion, followed by progressive fibrous connective tissue deposition in the bone marrow, resulting in bone marrow failure.
Paula de Melo Campos
doaj   +1 more source

CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms

Annals of Hematology
Polycythemia vera (PV) and Essential thrombcythemia (ET) are myeloproliferative neoplasms (MPNs) that can progress to secondary myelofibrosis, a complication associated with increased mortality. Circulating CD34-positive cells at diagnosis can be used to
Marine Demoy, Maxence Bauvais, Agathe Vely, Thomas Nicol, Jérémie Riou, Hortense Le Jeanne, Aurélien Bauduin, Hubert Rambaud, Françoise Boyer, Franck Geneviève, Agathe Boussaroque, Marie-Christine Copin, Valérie Ugo, Corentin Orvain, Damien Luque Paz   +14 more
doaj   +1 more source

Reticulosarcomatosis in primary myelofibrosis [PDF]

Cancer, 1968
openaire   +2 more sources

Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome

Clinics, 2013
OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2 V617F mutation status can predict clinical outcome.
Bruno Deltreggia Benites, Carolina Silva Costa Lima, Irene Lorand-Metze, Marcia Torresan Delamain, Gislaine Borba Oliveira, Daiane de Almeida, Carmino Antonio de Souza, Jose Vassallo, Katia Borgia Barbosa Pagnano   +8 more
doaj  

Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study

Therapeutic Advances in Hematology
Background: Secondary myelofibrosis (SMF) is characterized by the excessive deposition of fibrous tissue on top of the primary disease, often causing clinical manifestations to be overshadowed by the primary disease.
Han Xu, Yujie Xu, Mengying Wang, Chunxia Mao, Junxia Huang, Tianlan Li, Yan Gao, Shanshan Liu, Jingjing Zhou, Yi Zhang, Xianqi Feng   +10 more
doaj   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source